Search Results
1
Study Matches
Site for A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects with Moderate to Severe Hidradenitis Suppurativa
Hidradenitis Suppurativa: Phase 2 Subject and Investigator Blinded, 68 week study with phone call 20 weeks after last dose.
Hidradenitis Suppurativa (HS) is a chronic recurrent and debilitating skin condition that typically presents with deep and painful lesions. The most common areas affected are the armpits, the groin, and the anus and genitals area.
The purpose of the study is to find out if risankizumab is beneficial and well tolerated in patients with HS. Each subject will be assigned to 1 of 3 treatment groups, reassigned to a different treatment at week 16, and then receive risankizumab at week 20.
Amy Longenecker at alongenecker@pennstatehealth.psu.edu or 717-531-5136
All
18 year(s) or older
NCT03926169
Skin Conditions